WAC and ASP of Herceptin (trastuzumab) biosimilars in the US 2022

Published by
Matej Mikulic,
Nov 2, 2022
As of 2022, biosimilar Herzuma (trastuzumab-pkrb) launched at an average sales price of six percent less than Herceptin's ASP, while biosimilar Trazimera (trastuzumab-qyyp) launched at an average sales price of 19 percent less than Herceptin's. This statistic illustrates the wholesale acquisition cost and average sales price of Herceptin (trastuzumab) biosimilars in the United States.

Wholesale acquisition cost (WAC) and average sales price (ASP) of Herceptin (trastuzumab) biosimilars in the U.S. as of 2022

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

2022

Region

Worldwide

Survey time period

as of July 2022

Citation formats
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$199 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Drug prices in the U.S. "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Drug prices in the U.S.

Market overview

7

United States vs. abroad

7

Price increase

8

Biosimilars' effects

5

Consumers' views

5

Further Content: You might find this interesting as well

Topics

Drug pricing in the U.S.Global pharmaceutical industryPharmaceutical industry in the U.S.Health expenditures in the U.S.Americans without health insurance
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Learn more about how Statista can support your business.
Menu